Gilead Sciences (GILD) stock
Last close $166.43 on 2026-11-20 (-0.06%) · Sector: Healthcare
Gilead Sciences is an American biopharmaceutical company based in Foster City, California, that researches, develops, and sells medicines for serious diseases. It makes most of its money by selling prescription drugs, including treatments for HIV and liver disease, to patients, hospitals, and health systems.
Gilead's revenue grew 6.5% over the past year, and its gross margin, the share of each sales dollar left after direct product costs, is near 80%. The stock returned 31.4% over the past year, well ahead of the S&P 500's 4.7%, and it trades 5.7% below its 52-week high. Insiders sold about $41.6 million of stock in the last 90 days and made no purchases. After its last four earnings reports, the stock rose the next day twice and fell twice, with moves of 5.8%, 2.0%, 2.6%, and 3.1%.
Key numbers
- Market cap: $208.2B
- Revenue (last 12 months): $30.98B
- Revenue growth: +6.5%
- Gross margin: 79.9%
- Operating margin: -7.6%
- P/S: 6.7
- Debt to equity: 1.83
- Current ratio: 1.38
Quality score
Overall 15/100 · growth 35 · profitability 11 · financial health 0 · value None
Performance and risk
1-year return +31.4% vs S&P 500 +4.7% · volatility 27.2% (S&P 500 14.3%) · largest drop -22.0% · beta 0.36
Stock move the day after earnings
- 2026-02-10: +5.8%
- 2026-05-07: -2.0%
- 2026-08-04: -2.6%
- 2026-10-29: +3.1%
Insider trades (12 months)
Bought $0.0M · sold $108.8M
GILD stock research · GILD options calculator · Stocks to buy, hold or sell today
StrikeWright provides AI signals only, not financial advice.